Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute IV infusion every 21 days (3 weeks).

Trial Details

NCT ID
NCT07007273
Phase
PHASE2
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Pembrolizumab
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of soft ti…
  • Participants must have metastatic or advanced disease which could include recurrent, unresectable or multifocal lesions or in which resection would…
  • Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been dem…
  • Archival tumor tissue sample or newly obtained \[core, punch, incisional, or excisional\] biopsy of a tumor lesion not previously irradiated is ava…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →